<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04068974</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-OvaC-IIT-SHR1210-APA</org_study_id>
    <nct_id>NCT04068974</nct_id>
  </id_info>
  <brief_title>Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib for Recurrent Platinum-resistant Ovarian Cancer: a Phase 2 Single-arm Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intend to improve the progression-free survial of the recurrent&#xD;
      paltinum-resistant ovarian cancer. All the participants will receive camrelizumab combined&#xD;
      with apatinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The proportion of participants with tumor size reduction of a predefined amount and for a minimum time period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Up to two years</time_frame>
    <description>The time from treatment until objective tumor progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Up to two years</time_frame>
    <description>The proportion of patients with complete response, partial response or keep stable diease after accept treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Up to two years</time_frame>
    <description>The time from firstly complete response or partly response to progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety</measure>
    <time_frame>Up to two years</time_frame>
    <description>The quantity and degree of adverse event and serious adverse event from</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Recurrent Platinum-resistant Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab (SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle. Apatinib :250 mg po qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab (SHR-1210)</intervention_name>
    <description>Anticancer T-cell activity is regulated by multiple suppressive mechanisms, including tumour-expressed programmed cell death ligand 1 (PD-L1) signalling to the T-cell inhibitory receptor (programmed death protein 1 [PD-1]). Monoclonal antibodies like SHR-1210 that can block this pathway.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib is an oral small-molecule tyrosine kinase inhibitor that selectively binds to and inhibits VEGF receptor 2.</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with recurrent -resistant epithelial ovarian cancer, fallopian tube cancer&#xD;
             and primary peritoneal cancer previously received twice or more platinum chemotherapy&#xD;
             before enrolment;&#xD;
&#xD;
          2. Recurrence occurred within 6 months after the last platinum-containing chemotherapy&#xD;
             and had experienced at least one platinum-sensitive recurrent in the past.;&#xD;
&#xD;
          3. Aged 18-70 years;&#xD;
&#xD;
          4. An Eastern Cooperative Oncology Group performance status of 0-2;&#xD;
&#xD;
          5. According to the solid tumor efficacy evaluation standard (RECIST1.1) or i RECIST, at&#xD;
             least one measurable lesion, with maximum diameter &gt; 1 cm and lymph node metastasis &gt;&#xD;
             1.5 cm, and the target lesion is not suitable for surgical treatment; the target&#xD;
             lesion has not received radiotherapy or recurred in the field of radiotherapy.&#xD;
&#xD;
          6. Expected survival ≥ 4 months;&#xD;
&#xD;
          7. The function of vital organs meets the following requirements： Hemoglobin≥80g/L;&#xD;
             Absolute neutrophil count≥1.5*109/L；Platelets≥100&#xD;
&#xD;
             *109/L; Creatinine≤1.5 times ULN; Urea nitrogen≤2.5 times ULN; Total Bilirubin≤ULN;&#xD;
             ALT and AST ≤ 2.5 times ULN; Albumin≥25g/L; TSH≤ULN(if TSH is abnormal, normal T3 and&#xD;
             T4 also can acceptable)&#xD;
&#xD;
          8. The subject should be aware of the purpose of the study and the operations required by&#xD;
             the study and volunteer to participate in the study before sign the informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Primary platinum refractory patients (first platinum-containing chemotherapy with&#xD;
             recurrence within 6 months)&#xD;
&#xD;
          2. Previously exposed to other anti-angiogenic small-molecule TKI drugs, such as&#xD;
             pazopanib, sorafenib, regorafenib, cilnitraz, etc. or anti-angiogenic mAbs such as&#xD;
             bevacizumab ; or had used an anti-PD-1 antibody, an anti-CTLA-4 antibody, TCR-T, CAR-T&#xD;
             and other immune therapy; or 4 weeks before the first administration participated in&#xD;
             any other clinical trials of anticancer drugs; or before the first dose Live&#xD;
             attenuated vaccines are accepted within 4 weeks or during the study period.&#xD;
&#xD;
          3. Target lesions observed received radiotherapy&#xD;
&#xD;
          4. Other malignant tumors have occurred in the past 3 years..&#xD;
&#xD;
          5. Immunosuppressive drugs used within 14 days prior to the first use of SHR-1210,&#xD;
             excluding nasal and inhaled corticosteroids or physiological doses of systemic steroid&#xD;
             hormones (ie, no more than 10 mg/day of turmeric or equivalent drug physiological&#xD;
             dose) Other corticosteroids).&#xD;
&#xD;
          6. Late-stage patients with symptomatic, disseminated to visceral, short-term risk of&#xD;
             life-threatening complications (including uncontrolled large amounts of exudate&#xD;
             [thoracic, pericardium, abdominal cavity], pulmonary lymphangitis, and more than 30%&#xD;
             liver involvement patients).&#xD;
&#xD;
          7. Any active autoimmune diseases or a history of autoimmune diseases (including but not&#xD;
             limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased&#xD;
             thyroid function; subjects with vitiligo or complete remission asthma in childhood and&#xD;
             without any intervention, all above can be included; asthma requiring medical&#xD;
             intervention for bronchodilators should be excluded).&#xD;
&#xD;
        8 Metastatic foci of the central nervous system have significant symptoms, such as&#xD;
        headache, cerebral edema and blurred vision 9. CT or MRI showed tumor lesion 5mm away from&#xD;
        the great blood vessel, or tumor invading the local great blood vessel, or accompanied by&#xD;
        tumor thrombus formation of the great vein (inferior vena cava of iliac vessel, superior&#xD;
        vena cava of pulmonary static vein) 10. Uncontrollable hypertension (systolic blood&#xD;
        pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, despite with the optimal medical&#xD;
        treatment.&#xD;
&#xD;
        11. Grade II or higher myocardial ischemia, myocardial infarction or poor control&#xD;
        arrhythmia (including male with QTc interval ≥ 450ms, or female with QTc interval≥ 470ms).&#xD;
        According to NYHA criteria, grade III to IV cardiac insufficiency, or cardiac color Doppler&#xD;
        ultrasound examination showed left ventricular ejection fraction (LVEF) &lt;50%; myocardial&#xD;
        infarction occurred within 6 months before enrollment, New York Heart Association Level II&#xD;
        or above failure, uncontrolled angina, uncontrolled severe ventricular arrhythmia,&#xD;
        pericardial disease with clinically significant, or electrocardiogram suggesting acute&#xD;
        ischemia or abnormal active conduction system.&#xD;
&#xD;
        12, Abnormal coagulation (INR &gt; 1.5 or prothrombin time (PT) &gt; ULN + 4 seconds or APTT &gt;&#xD;
        1.5ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy.&#xD;
&#xD;
        13. Half of a teaspoons (2.5 ml) or more hemoptysis was found within the first 2 months or&#xD;
        there were significant clinical bleeding symptoms or clearly propensity bleeding within 3&#xD;
        months before participant in the study, such as gastrointestinal bleeding, hemorrhagic&#xD;
        gastric ulcer, fecal occult blood ++ or above in baseline or vasculitis; artery or venous&#xD;
        thrombosis events within 6 months prior to the study, such as cerebrovascular accidents&#xD;
        (Including transient ischemic attacks, cerebral hemorrhage, cerebral infarction, deep vein&#xD;
        thrombosis and pulmonary embolism.&#xD;
&#xD;
        14. Severe infections within 4 weeks prior to accept medication (eg, intravenous infusion&#xD;
        of antibiotics, antifungal or antiviral drugs), or unexplained fever during screening/first&#xD;
        administration &gt;38.5 °C 15. Those who have a history of psychotropic drug abuse and are&#xD;
        unable to quit or have mental disorders.&#xD;
&#xD;
        16. Major surgical procedures were performed within 4 weeks before the first&#xD;
        administration. Or open wounds or fractures.&#xD;
&#xD;
        17. There are obvious factors affecting oral drug absorption, such as inability to swallow,&#xD;
        chronic diarrhea and intestinal obstruction. Or sinus or perforation of empty organs within&#xD;
        6 months.&#xD;
&#xD;
        18. Routine urine test indicated that urinary protein (++) or more, confirmed urinary&#xD;
        protein (&gt;1.0 g) within 24 hours.&#xD;
&#xD;
        19. Patients with a history of allergy may be potentially allergic or intolerant to&#xD;
        Apatinib and biological agents SHR-1210.&#xD;
&#xD;
        20. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency&#xD;
        syndrome (AIDS), active hepatitis B (HBV DNA (&gt; 500 IU/ml), hepatitis C (hepatitis C&#xD;
        antibody positive, and HCV-RNA higher than the lower limit of the analysis method) or&#xD;
        co-infection with hepatitis B and hepatitis C.&#xD;
&#xD;
        21. There is any situation that may damage the subject or cause the subject to fail to meet&#xD;
        or implement the research requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pan lingya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pan Lingya</last_name>
    <phone>010-69156204</phone>
    <email>Panly@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pan Lingya</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lingya Pan</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>Ovarian Cancer</keyword>
  <keyword>Recurrent Platinum-resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

